Ralph Salloum
Children's Oncology Group · Dana-Farber Cancer Institute · Pediatric Brain Tumor Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ralph Salloum as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:46 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05382338 · A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing LossChildren's Oncology Group · recruiting · Childhood Medulloblastoma · principal investigator
- Ph1/Ph2NCT03904862 · Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have SurgeryPediatric Brain Tumor Consortium · terminated · Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma · study chair
- Ph1NCT03598244 · Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsNational Cancer Institute (NCI) · active not recruiting · Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase I/II Study of 177Lu-DOTATATE in Children and Young Adults with Recurrent/Progressive High-Grade CNS Tumors and Meningiomas which Express Somatostatin Type 2A Receptors [9/24/21 IND]R01FD007532 · FDA · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · fiscal years 2022 to 2024 · $485,894 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT05382338
- Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumorsUM1CA081457 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Ira J Dunkel, Arzu Onar-Thomas · fiscal years 2014 to 2026Named on NCT03904862, NCT03598244
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:46 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 82 citationsRCR 2.5
- Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.Br J Haematol · 200977 citationsRCR 1.6
- A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).J Neurooncol · 202044 citationsRCR 1.8
- Testing Cessation Messages for Cigarette Package Inserts: Findings from a Best/Worst Discrete Choice Experiment.Int J Environ Res Public Health · 201821 citationsRCR 1.6
- When does an episode of care for cancer begin?Med Care · 201319 citationsRCR 0.6
- An Implementation Trial to Improve Tobacco Treatment for Cancer Patients: Patient Preferences, Treatment Acceptability and Effectiveness.Int J Environ Res Public Health · 202015 citationsRCR 1.0
- A point-of-care pilot randomized intervention to connect patients with cancer-induced financial toxicity to telehealth financial counseling.Cancer Causes Control · 202414 citationsRCR 2.3
- Mixed methods evaluation of vaping and tobacco product use prevention interventions among youth in the Florida 4-H program.Addict Behav · 202313 citationsRCR 2.9
- LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors.J Chromatogr B Analyt Technol Biomed Life Sci · 20209 citationsRCR 0.5
- 2 citationsRCR 0.8